The Regulation (EU) No. 536/2014, commonly referred to as the EU Clinical Trials Regulation (EU CTR), particularly in Article 371, emphasises the necessity for trial sponsors to provide a summary, known as a "lay summary" or "LS," tailored to be easily understood by non-experts, for each clinical trial involving pharmaceuticals submitted to the EU Database. This database plays a crucial role in the EU's Clinical Trials Information System (CTIS), serving as a central repository for pertinent trial information.
Collaborating with a lay writing specialist, I had the task of creating such a document for a clinical trial they were tasked with producing. With the provided content, my role was to design a visually appealing leaflet intended to highlight and clarify key facts in a manner accessible to the target audience. Through a thoughtful integration of design elements and content presentation, the aim was to ensure that the lay summary not only effectively communicated essential information but also resonated with its intended readership.
This was achieved by using neutral colours, thoughtfully chosen iconography, and incorporating warm, friendly imagery. These design elements were carefully selected to inspire trust and create a welcoming atmosphere, inviting viewers to engage with ease and comfort.
If you're looking for design support for your business then look no further. Lets talk.